.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Novartis
Cerilliant
Cipla
Johnson and Johnson
Teva
Merck
Cantor Fitzgerald
Queensland Health
Baxter

Generated: September 21, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Radiolabeled compounds for thrombus imaging
Abstract:This invention relates to radiolabeled scintigraphic imaging agents, and methods and reagents for producing such agents. Specifically, the invention relates to specific binding compounds, including peptides, that bind to a platelet receptor that is the platelet GPIIb/IIIa receptor, methods and kits for making such compounds, and methods for using such compounds labeled with technetium-99m via a covalently-linked radiolabel-binding moiety to image thrombi in a mammalian body.
Inventor(s): Dean; Richard T. (Bedford, NH), Lister-James; John (Bedford, NH)
Assignee: Diatide, Inc. (Londonderry, NH)
Filing Date:Jun 19, 1998
Application Number:09/100,536
Claims:1. A method of imaging a thrombus within a mammalian body comprising the steps of:

a) administering an effective diagnostic amount of a radiolabeled reagent comprising

i) a radiolabel complexing moiety; and

ii) a platelet glycoprotein IIb/IIIa-binding compound covalently linked to the moiety and having a molecular weight less than 10,000 daltons;

wherein said reagent is capable of inhibiting human platelet aggregation in platelet-rich plasma by 50% when present at a concentration not greater than about 1 .mu.M; and

b) detecting a radiolabel localized at said thrombus.

2. The method of claim 1, wherein the radiolabel is selected from the group consisting of technetium-99m, indium-111, and gallium-68.

3. The method of claim 2, wherein the radiolabel is technetium-99m.

4. The method of claim 3, wherein the reagent is CH.sub.2 CO--Y.sub.D ApcGDCGGC.sub.Acm GC.sub.Acm GGC.amide.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Argus Health
Accenture
Chubb
Farmers Insurance
Cipla
Dow
Harvard Business School
Fish and Richardson
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot